Pmu1a, a novel spider toxin with dual inhibitory activity at pain targets hNa V 1.7 and hCa V 3 voltage‐gated channels
The FEBS Journal · 2023
DOI: 10.1111/febs.16773 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, 2023. Verfasst von Julien Giribaldi und 10 weiteren Autor:innen. Beteiligte Einrichtung: IBMM, CNRS, ENSCM, Université de Montpellier, France. Hauptthemen laut MEDLINE: Spider Venoms, Spiders. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: Intramural Research Program of the National Cancer Institute, Agence Nationale de la Recherche, Australian Research Council.
Abstract (Originalsprache)
Venom‐derived peptides targeting ion channels involved in pain are regarded as a promising alternative to current, and often ineffective, chronic pain treatments. Many peptide toxins are known to specifically and potently block established therapeutic targets, among which the voltage‐gated sodium and calcium channels are major contributors. Here, we report on the discovery and characterization of a novel spider toxin isolated from the crude venom of Pterinochilus murinus that shows inhibitory activity at both hNa V 1.7 and hCa V 3.2 channels, two therapeutic targets implicated in pain pathways. Bioassay‐guided HPLC fractionation revealed a 36‐amino acid peptide with three disulfide bridges named μ/ω‐theraphotoxin‐Pmu1a (Pmu1a). Following isolation and characterization, the toxin was chemically synthesized and its biological activity was further assessed using electrophysiology, revealing Pmu1a to be a toxin that potently blocks both hNa V 1.7 and hCa V 3. Nuclear magnetic resonance structure determination of Pmu1a shows an inhibitor cystine knot fold that is the characteristic of many spider peptides. Combined, these data show the potential of Pmu1a as a basis for the design of compounds with dual activity at the therapeutically relevant hCa V 3.2 and hNa V 1.7 voltage‐gated channels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IBMM, CNRS, ENSCM, Université de Montpellier, France.
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
- Institute of Functional Genomics, CNRS, INSERM, Montpellier University, France.
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Qld, Australia.
- School of Pharmacy, The University of Queensland, Woolloongabba, Qld, Australia.
- Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Qld, Australia.
ORCID-Profile: Sébastien Dutertre
Förderung
- Intramural Research Program of the National Cancer Institute
- Agence Nationale de la Recherche
- Australian Research Council
- National Health and Medical Research Council
Zitieren
APA
Giribaldi, J., Chemin, J., Tuifua, M., Deuis, J. R., Mary, R., Vetter, I., Wilson, D. T., Daly, N. L., Schroeder, C. I., Bourinet, E., & Dutertre, S. (2023). Pmu1a, a novel spider toxin with dual inhibitory activity at pain targets hNa V 1.7 and hCa V 3 voltage‐gated channels. The FEBS Journal. https://doi.org/10.1111/febs.16773
Vancouver
Giribaldi J, Chemin J, Tuifua M, Deuis JR, Mary R, Vetter I, et al. Pmu1a, a novel spider toxin with dual inhibitory activity at pain targets hNa V 1.7 and hCa V 3 voltage‐gated channels. The FEBS Journal. 2023. doi:10.1111/febs.16773
BibTeX
@article{Giribaldi2023,
author = {Giribaldi, Julien and Chemin, Jean and Tuifua, Marie and Deuis, Jennifer R and Mary, Rosanna and Vetter, Irina and Wilson, David T and Daly, Norelle L and Schroeder, Christina I and Bourinet, Emmanuel and Dutertre, Sébastien},
title = {Pmu1a, a novel spider toxin with dual inhibitory activity at pain targets hNa V 1.7 and hCa V 3 voltage‐gated channels},
journal = {The FEBS Journal},
year = {2023},
doi = {10.1111/febs.16773}
}
EUVIMED